文献速递泌尿生殖妇产影像US

在低危人群中验证ADNEX模型与IOTA两步策略并评估附件肿物随访期间并发症风险

Validation of ADNEX and IOTA two-step strategy and estimation of risk of complications during follow-up of adnexal masses in low-risk population.
PubMed 文献 · Ultrasound Obstet Gynecol · 2024-08-16

本研究在西班牙巴塞罗那Dexeus大学医院单中心前瞻性观察性IOTA5研究的中期数据中,回顾性验证ADNEX模型(不含CA125)与IOTA两步策略对低危门诊附件肿物的良恶性鉴别能力,并评估超声形态良性肿物保守随访的并发症风险。ADNEX模型AUC为0.95(95%CI 0.89-0.98),两步策略AUC为0.94(95%CI 0.88-0.97);在1472例经经验丰富超声医师模式识别判为良性并随访的患者中,5年累积扭转发生率为0%(95%CI 0-0.2%),囊肿破裂为0.1%(95%CI <0.1-0.4%),交界性肿瘤为0.2%(95%CI 0.1-0.6%),浸润性恶性为0.2%(95%CI 0.1-0.6%)。结论认为两种方法在低危人群鉴别良恶性表现良好,超声形态良性者保守管理安全。

要点

  • ADNEX模型(不含CA125)鉴别附件肿物良恶性AUC为0.95(95%CI 0.89-0.98)。
  • IOTA两步策略AUC为0.94(95%CI 0.88-0.97),恶性风险阈值<3%时临床效用优于ADNEX模型。
  • 经验丰富超声医师模式识别判为良性并随访者,5年累积扭转发生率0%(95%CI 0-0.2%)。

核心结论

  • ADNEX模型与IOTA两步策略在低危人群中鉴别附件肿物良恶性表现良好。
  • 在该人群中,超声形态良性肿物的保守管理是安全的。

研究设计与样本

  • 单中心研究,在西班牙巴塞罗那Dexeus大学医院开展,使用正在进行的前瞻性观察性IOTA Phase-5(IOTA5)研究的中期数据。
  • 纳入2012年6月至2016年9月在一家提供妇科癌症筛查的私立中心连续检出的附件肿物患者,随访至2020年2月。
  • 以组织学(若患者接受手术)或12个月(范围10-14个月)临床与超声随访结局将肿瘤分类为良性或恶性,结局不确定时采用多重插补。
  • 回顾性评估ADNEX模型(不含CA125)与IOTA两步策略区分良恶性的能力,评估指标包括判别力(AUC)、校准、分类(敏感度与特异度)和临床效用(净获益)。
  • 共招募2654例患者,应用排除标准后2039例新检出肿物患者纳入模型验证。

关键影像表现/征象

  • 2039例纳入验证的肿物中,1684例(83%)为良性,49例(2%)为恶性,306例(15%)结局不确定并插补。
  • 在1472例(72%)经经验丰富超声医师模式识别判为良性并接受临床与超声随访的患者中,5年累积自发消退率为66%(95%CI 63-69%)。

诊断标准与关键数值

  • ADNEX模型(不含CA125)鉴别良恶性AUC为0.95(95%CI 0.89-0.98)。
  • IOTA两步策略鉴别良恶性AUC为0.94(95%CI 0.88-0.97)。
  • 恶性风险阈值<3%时,IOTA两步策略的临床效用优于ADNEX模型。
  • 校准性能因恶性例数少导致置信区间很宽而无法有意义解读。
  • 保守管理组5年累积发生率:自发消退66%(95%CI 63-69%),扭转0%(95%CI 0-0.2%),囊肿破裂0.1%(95%CI <0.1-0.4%),交界性肿瘤0.2%(95%CI 0.1-0.6%),浸润性恶性0.2%(95%CI 0.1-0.6%)。

临床应用与阅片要点

  • 在低危门诊人群可依据经验丰富超声医师的模式识别将肿物判为良性并纳入临床与超声随访。

局限性

  • 校准性能因恶性例数少导致置信区间很宽而无法有意义解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the ability of the Assessment of Different NEoplasias in the adneXa (ADNEX) model and the International Ovarian Tumour Analysis (IOTA) two-step strategy to predict malignancy in adnexal masses detected in an outpatient low-risk setting, and to estimate the risk of complications in masses with benign ultrasound morphology managed using clinical and ultrasound follow-up.

METHODS: This single-center study was performed at Hospital Universitari Dexeus, Barcelona, Spain, using interim data from the ongoing prospective observational IOTA Phase-5 (IOTA5) study. The primary aim of the IOTA5 study is to describe the cumulative incidence of complications during follow-up of adnexal masses classified as benign on ultrasound examination. Consecutive patients with an adnexal mass detected between June 2012 and September 2016 in a private center offering screening for gynecological cancer were included and followed up until February 2020. Tumors were classified as benign or malignant based on histology (if patients underwent surgery) or the outcome of clinical and ultrasound follow-up at 12 (range, 10-14) months. Multiple imputation was used when outcomes were uncertain. The ability of the ADNEX model without CA125 and of the IOTA two-step strategy to distinguish benign from malignant masses was evaluated retrospectively using the prospectively collected data. We assessed performance with regard to discrimination (area under the receiver-operating-characteristics curve (AUC)), calibration, classification (sensitivity and specificity) and clinical utility (Net Benefit). In the group of patients with a mass judged to be benign who were selected for conservative management, we evaluated the occurrence of spontaneous resolution or any mass complication during the first 5 years of follow-up by assessing the cumulative incidence of malignancy, torsion, cyst rupture and minor mass complications (inflammation, infection or adhesions) and the time to occurrence of an event.

RESULTS: A total of 2654 patients were recruited to the study. After application of exclusion criteria, 2039 patients with a newly detected mass were included for the model validation. Of those, 1684 (83%) masses were benign, 49 (2%) masses were malignant and, for 306 (15%) masses, the outcome was uncertain and therefore imputed. The AUC was 0.95 (95% CI, 0.89-0.98) for ADNEX without CA125 and 0.94 (95% CI, 0.88-0.97) for the two-step strategy. Calibration performance could not be meaningfully interpreted because the small number of malignancies resulted in very wide confidence intervals. The two-step strategy had better clinical utility than did the ADNEX model at malignancy risk thresholds < 3%. There were 1472 (72%) patients whose mass was judged to be benign based on pattern recognition by an experienced ultrasound examiner and were managed with clinical and ultrasound follow-up. In this group, the 5-year cumulative incidence was 66% (95% CI, 63-69%) for spontaneous resolution of the mass, 0% (95% CI, 0-0.2%) for torsion, 0.1% (95% CI, < 0.1-0.4%) for cyst rupture, 0.2% (95% CI, 0.1-0.6%) for a borderline tumor and 0.2% (95% CI, 0.1-0.6%) for invasive malignancy.

CONCLUSIONS: The ADNEX model and IOTA two-step strategy performed well to distinguish benign from malignant adnexal masses detected in a low-risk population. Conservative management is safe for masses with a benign ultrasound appearance in this population. © 2024 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Pascual MA, Vancraeynest L, Timmerman S, et al. Validation of ADNEX and IOTA two-step strategy and estimation of risk of complications during follow-up of adnexal masses in low-risk population. Ultrasound Obstet Gynecol. 2024. PMID: 38477179. doi:10.1002/uog.27642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。